Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Expenses (2016 - 2025)

Amphastar Pharmaceuticals has reported Operating Expenses over the past 13 years, most recently at $58.8 million for Q4 2025.

  • Quarterly results put Operating Expenses at $58.8 million for Q4 2025, up 41.65% from a year ago — trailing twelve months through Dec 2025 was $224.4 million (up 32.3% YoY), and the annual figure for FY2025 was $215.7 million, up 28.03%.
  • Operating Expenses for Q4 2025 was $58.8 million at Amphastar Pharmaceuticals, down from $73.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for AMPH hit a ceiling of $73.3 million in Q3 2025 and a floor of $26.4 million in Q3 2021.
  • Median Operating Expenses over the past 5 years was $39.5 million (2022), compared with a mean of $41.0 million.
  • Biggest five-year swings in Operating Expenses: decreased 19.94% in 2021 and later soared 63.34% in 2025.
  • Amphastar Pharmaceuticals' Operating Expenses stood at $32.0 million in 2021, then rose by 4.23% to $33.3 million in 2022, then increased by 26.47% to $42.2 million in 2023, then dropped by 1.56% to $41.5 million in 2024, then surged by 41.65% to $58.8 million in 2025.
  • The last three reported values for Operating Expenses were $58.8 million (Q4 2025), $73.3 million (Q3 2025), and $44.3 million (Q2 2025) per Business Quant data.